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Epinephrine-promoted r lease of [3H]guanylylimidodiphosphate ([3H]Gpp(NH)p) from human platelet 
membranes has been used to probe the interactions between alphaz-adrenergic re eptors and Ni, the 
guanine nucleotide binding protein that couples those receptors to an inhibition of adenylate cyclase 
activity. We show here that ADP, which also acts through specific platelet receptors to inhibit adenylate 
cyclase activity, also promotes the release of [3H]Gpp(NH). The amount of [3H]Gpp(NH)-release licited 
by epinephrine and by ADP together is equal to the sum of the amounts released by the two agents acting 
individually. Furthermore the maximal amounts of [3H]Gpp(NH)-release licited by each of the two agents 
approximates the numbers of receptors for ADP and epinephrine present in the platelet membranes. These 
results suggest hat the two receptor types interact with distinct portions of the pool of Ni molecules and 
that each receptor initiates guanine-nucleotide exchange on a single molecule of Ni. 
Alphaz-adrenergic receptor ADP receptor Adenylate cyclase 
Nucleotide-binding protein Guanine nucleotide 
1. INTRODUCTION 
Distinct guanine nucleotide-binding proteins, 
termed Ns and Ni, transduce hormonal stimulation 
and inhibition of adenylate cyclase (review [l-4]). 
Human platelets have been a useful system for 
studying the regulation of adenylate cyclase by N, 
and Ni because platelets are easily obtainable as a 
homogeneous preparation and because several 
types of membrane receptors stimulate and inhibit 
platelet adenylate cyclase activity. The most 
thoroughly studied of the receptors that act via Ni 
to inhibit adenylate cyclase are the alphaz-adrener- 
gic (az-adrenergic) receptors through which epine- 
phrine modulates several platelet functions in- 
cluding secretion and aggregation. 
This approach, originally described in [5,6], 
studies of beta-adrenergic (%adrenergic) stimula- 
tion of turkey erythrocyte adenylate cyclase [5,6], 
has been less widely used for studying receptor in- 
teractions with Ni. Recently it was shown [7] that 
[‘HI guanylylimidodiphosphate ([‘HI Gpp(NH)p) 
will bind to platelet membranes and that its release 
from the membrane binding sites is promoted by 
epinephrine acting through an cuz-adrenergic recep- 
tor. In order to probe receptor-Ni stoichiometry we 
measured [3H]Gpp(NH)p-release promoted by 
ADP, which also acts through specific receptors to 
inhibit adenylate cyclase in platelets [8,9]. 
2. EXPERIMENTAL 
One approach to studying the interactions be- Our method was adapted from that in [7]. 
tween hormones and the coupling proteins is to Platelets were isolated and washed as in [lo], and 
evaluate the exchange or release of bound guanine were then suspended in 5 mM Tris-HCl, 5 mM 
nucleotides from N promoted by receptor agonists. EDTA at pH 7.5. The platelets were ruptured by 3 
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freeze-thaw cycles using liquid nitrogen. The 
broken platelets were then suspended in ice-cold 50 
mM Tris-HCl, 8 mM MgC12, 2 mM dithiothreitol, 
0.5 mM EGTA at pH 7.5, and this buffer was used 
in all subsequent steps. The membranes were wash- 
ed twice by centrifugation at 30000 x g for 15 min 
at 4°C with intervening resuspension using a 
Tekmar homogenizer, and the final pellet was 
stored at - 70°C. On the day of the experiment he 
platelets were thawed, washed once, and were 
suspended at l-2 mg protein/ml. After incubating 
with 0.3 PM [3H]Gpp(NH)p (9-13 Ci/mmol, 
Amersham) for 3 min at 25”C, the platelets were 
washed 3-times. Subsequent ADP-promoted 
release was not increased when membranes were 
incubated with a higher concentration of 
[3H]Gpp(NH)p (0.6 or 1.2 PM). 
Release of [3H]Gpp(NH)p was promoted by 
ADP in the presence of GTP but not in its absence 
(fig. 1). The ECX, concentration of ADP was - 1 
PM; release was maximal at 1OOpM (fig. 2); these 
concentrations are similar to those required for in- 
[3H]Gpp(NH)p-release was initiated by adding 
0.1 ml of the ice-cold platelet membranes to 0.9 ml 
of warmed buffer (37°C) containing 10 PM GTP 
and epinephrine or ADP as indicated. In ex- 
periments involving epinephrine, 0.1 mg/ml ascor- 
bic acid was included in the buffer to block oxida- 
tion of the catecholamine. After 3 min the contents 
of each tube were filtered with suction through a 
dry fiberglass filter (Whatman GF/C) held in a 
Millipore filter manifold. Radioactivity in an ali- 
quot (usually 0.66 ml) of the filtrate was then 
counted. 
The protein content of platelet membranes was 
determined by the method in [l l] using bovine 
serum albumin standards. 
Fig. 1. GTP requirement for [3H]Gpp(NH)p-release pro- 
moted by ADP. Platelet membranes were incubated with 
[3H]Gpp(NH)p and washed, and radioactivity subse- 
quently released from the membranes was measured in 
the absence (open bars) and presence (hatched bars) of 
100 Frn ADP. On the left are shown the results in the 
absence of GTP during a 3-min incubation. The other 
results were obtained in the presence of 10pM GTP with 
either a 3 min (center) or 6 min (right) release incuba- 
tion. The final protein concentration was 0.112 mg/ml, 
and an aliquot of 0.66 ml of the filtrate was counted. 
The specific activity was 13.9 cpm/fmol; thus 1 cpm 
equalled 1 fmol/mg in this experiment. The total 
amount of [3H]Gpp(NH)p bound to the membranes in 
The number of az-adrenergic receptors was 
determined by Scatchard analysis of saturation- 
binding isotherms performed with [3H]yohimbine 
[lOI. 
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3. RESULTS 
3.1. [3H]Gpp(NH)p-release promoted by ADP 
In a previous report, adenylylimidodiphosphate 
[App(NH)p] was included in the incubation of 
platelet membranes with [3H]Gpp(NH)p to reduce 
non-specific binding of [3H]Gpp(NH)p to those 
membranes [7]. We used App(NH)p in preliminary 
experiments but observed no subsequent ADP- 
promoted [3H]Gpp(NH)p-release; presumably 
App(NH)p acts as an antagonist at ADP receptors. 
Therefore we did not use App(NH)p in the ex- 
periments reported here. 
Fig. 2. Dose-response curve for ADP-promoted 
[3H]Gpp(NH)p-release. Platelet membranes were 
prelabeled with [3H]Gpp(NH)p, and radioactivity 
specifically released in 3 min by various concentrations 
of ADP in the presence of 10,uM GTP was determined. 
14 
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each tube was 24000 cpm. 
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hibition of adenylate cyclase ]8,9]. ADP-promoted 
[3H]Gpp(NH)p-release was similar in 3- and 6min 
incubations. These results show that the proper- 
ties of ADP-promoted [3H]Gpp(NH)p-release 
resemble those of epinephrine-promoted 
[3H]Gpp(NH)p-release reported in 171. 
3.2. Additivity of f3HJGpp(iVH)p-i-e/ease 
promoted by epinephrine and ADP 
In 7 experiments we simultaneously measured 
basal [3H]Gpp(NH)p-release and release in the 
presence of IOOpM epinephrine, 1~~M ADP, or 
both (fig. 3). The release promoted by the two 
agents was precisely additive. Epinephrine released 
260 f 30 fmol [3H]Gpp(NH)p/mg membrane pro- 
tein (mean rt standard error). Release promoted 
by ADP was 834 f 29 fmollmg. When both 
agents were included together the release was 1092 
r 124 fmollmg, a figure virtually identical to the 
EXPERIMENT 
Fig. 3. Additivity of [3H]Gpp(NH)p-release by ADP and 
epinephrine. Platelet membranes were prelabeled with 
[3H]Gpp(NH)p, and were washed. The amount of 
specific release of radioactivity was then measured in the 
presence of 100 pM epinephrine (vertical stripes), 100 
,LLM ADP (horizontal stripes), or both (hatched bars). 
Basal release was subtracted from total release in the 
presence of hormone to obtain the specific release plot- 
ted here. The results of 7 individual experiments are 
shown, each experiment performed with 6 replicates. Ex- 
periments l-3 were incubated at 25°C; experiments 4-7 
at 37°C. Note that the bars representing epinephrine- 
promoted release begin at the top of the bars beneath 
them and not at the bottom of the graph. The mean 
results are reported in the text. 
Table 1 
Parallel determinations of receptor number and 
[3H]Gpp(NH)p-release 
Experiment (3H]Gpp(NH)p- IL,, 
release (fmol/mg 
(fmol/mg protein) 
protein) 
Ratio 
1 230 379 0.61 
2 195 268 0.73 
3 179 380 0.47 
average 201 342 0.60 
[‘H]Gpp(NH)p-release was determined in 3 separate x- 
periments. Receptor number was determined in each ex- 
periment from a Scatchard plot derived from saturation- 
binding isotherms using [‘Hlyohimbine [lo] 
sum of the amounts of release promoted by the 
two agents acting individually (1094 f 126 
fmol/mg). 
3.3. Simultaneous determination of cyz-adrenergic 
receptor namber and epinephrine-promoted 
tHjGpp@VH)p-rerease. 
The amount of [3H]Gpp(NH)p specifically re- 
leased by epinephrine and ADP was approximately 
equal to the reported number of az-adrenergic [lo] 
and ADP [12,13] receptors present on platelet 
membranes, respectively. To make the compari- 
son directly, we measured epinephrine-mediated 
[“H]Gpp(NH)p-release and az-adrenergic receptor 
number in parallel (table 1). The amount of 
[3H]Gpp(NH)p-release was 60% of the number of 
receptors present. 
4. DISCUSSION 
The amount of [3H]Gpp(NH)p-release specifi- 
cally elicited by epinephrine (release in the presence 
of epinephrine minus basal release) was 60% of the 
number of a*-adrenergic receptors present (table I). 
It is known that platelets contain 3 times more 
ADP receptors than cuz-adrenergic receptors [12,131 
and we found that ADP released 3.2-times more 
f3H]Gpp(NH)p than did epinephrine (fig. 3). The 
calculations of receptor-spe~i~c [3H]Gpp(NH)- 
release, however, most likely underestimate the 
number of Ni molecules on which an agonist- 
stimulated guanine-nucleotide exchange reaction 
15 
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occurs. The rate of basal [3H]Gpp(NH)-release 
(with GTP present) is considerable, and is likely to 
be from Ni as well as from other sites. Therefore 
some hormone-stimulated guanine nucleotide ex- 
change likely occurs on Ni molecules from which 
basal [3H]Gpp(NH)p-release also occurs, and this 
will not be included in the calculation of hormone- 
specific release. We think it is most likely that each 
cyz-adrenergic and ADP receptor interacts with, 
and promotes guanine-nucleotide xchange on a 
single Ni molecule. Similarly, others have found 
that ,&adrenergic receptor number is approxi- 
mately equal to the amount of guanine nucleotide 
release from N, promoted by ,B-adrenergic agonists 
[6,14], suggesting that stimulatory receptors are 
also functionally related to their coupling protein 
with a 1: 1 stoichiometry. However, reconstitution 
studies of solubilized and partially purified recep- 
tors and N, have suggested that receptors interact 
with NZ catalytically, that one receptor can interact 
with several N, molecules [ 15,161. 
Our finding that ADP and epinephrine additive- 
ly stimulate [3H]Gpp(NH)p indicates that each 
type of receptor probably interacts with different 
Ni molecules. Several explanations are con- 
ceivable. Subpopulations of Ni may exist, perhaps 
each physically associated with one type of recep- 
tor. Alternatively, the entire pool of Ni may be 
equivalent, and the amount of [3H]Gpp(NH)- 
release may be limited by receptor number. Similar 
experiments performed with receptors linked to N, 
have lead to different conclusions. Release of 
labeled nucleotides from N, of frog erythrocyte 
membranes is promoted by isoproterenol and pro- 
staglandin Er , and each agent alone and both 
together promoted identical amounts of nucleotide 
release. This observation led the authors to con- 
clude that the two types of receptors interact with 
the same (and presumably the entire) pool of N, 
1141. 
Two methods have been used to study agonist- 
stimulated guanine-nucleotide interaction with N, 
and Ni. GTP hydrolysis can be directly measured 
[5,17], or one can measure the release of 
[3H]Gpp(NH)p, which is thought to correspond to 
the release of GDP following GTP hydrolysis 
[6,7]. In human platelet membranes, epinephrine 
elicits 0.26 pmol of [3H]Gpp(NH)p release/mg 
protein (fig. 3) and stimulates 28 pmol. mg 
protein-’ f min -’ GTP hydrolysis [17], yielding a 
16 
rate of - 100 molecules/min for each coupled Ni. 
In turkey erythrocyte membranes, the,&adrenergic 
agonist isoproterenol stimulated 1.75 pmol [3H] 
Gpp(NH)p-release/mg protein [6] and 4.5 pmol 
GTP hydrolysis. mg protein-’ . min-’ [5], in- 
dicating that each N, coupled to ,B-adrenergic 
receptors hydrolyze GTP at the rate of 2-3 
molecules/min. Additional data from other 
systems will be required to determine whether the 
differences in GTP hydrolysis rate between platelet 
Ni and turkey erythrocyte N, reflect fundamental 
differences in N, and N, action. 
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